Investigating a new pathway for repairing myelin in Multiple Sclerosis
Official title: GLT-1/EAAT2 signaling as a novel player in myelin repair
Funded at Virginia Commonwealth University · NIH-10989063 · Data updated 2026-11-12
This study is looking at how a certain process in the brain might help repair the protective covering around nerves in people with Multiple Sclerosis, with the hope of finding new treatments that could improve their quality of life and slow down the disease.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | July 9, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $426,938 |
| NIH project number | 1R21NS135262-01A1 |
| Project ID | NIH-10989063 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Multiple Sclerosis, particularly those experiencing progressive symptoms.
✕Less likely to help
Patients with other neurological conditions unrelated to myelin damage may not benefit from this research.
What this research studies
This research focuses on understanding how a specific signaling pathway involving glutamate may contribute to the repair of myelin in the central nervous system, particularly in patients with Multiple Sclerosis (MS). The study aims to identify new therapeutic targets that could promote myelin regeneration, which is crucial for restoring function and reducing disability in MS patients. By exploring the mechanisms behind myelin repair, the research seeks to develop innovative treatments that go beyond current therapies, which primarily address inflammation. Patients may benefit from potential new therapies that could enhance their quality of life and slow disease progression.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that promote myelin repair, potentially improving outcomes for patients with Multiple Sclerosis.
How similar studies have gone: While the approach of targeting myelin repair is still emerging, there is growing evidence from other studies suggesting that promoting myelin regeneration could significantly impact MS treatment.
Where this research is happening
-
Virginia Commonwealth University
Richmond, United States Active
Researchers
- Principal investigator: Fuss, Babette — Virginia Commonwealth University
- Study coordinator: Fuss, Babette
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.